Application of dexmedetomidine in patients undergoing cervical Key hole surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064716

Enrollment

Unknown

Registered

2022-10-15

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic trigeminal neuralgia

Interventions

L group:Dex low dose

H group:Dex high dose

N group:Normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for cervical spondylotic radiculopathy; 2. ASA level I to II; 3. Age 18-80 years; 4.BMI 20~30 kg/m 2; 5. Hypertension is within Grade II or controlled with medication; 6. Fasting blood glucose of diabetes<8.0 mol/L; 6. No obvious cardiovascular, lung, liver, kidney and other important organ diseases, no electrolyte disorders or infections, and no immune or endocrine system diseases.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to dexmedetomidine and have recently received sedative and antidepressant treatment; 2. Patients who refuse to undergo this trial.

Design outcomes

Primary

Measure	Time frame
NRS Score;Heart rate;5/5000 Mean arterial pressure;	—

Countries

China

Contacts

Public ContactZhang Enming

Jiaxing First Hospital

zhangzhang980226@163.com+86 15045965687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026